How removing an 's' can change the perception of migraines
Amgen and Novartis enlisted Arnold Worldwide, Wavemaker, and Starcom Media Group for its Speak Your Migraine campaign.
How Adept Pharma tackled the opioid crisis head on
The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
Sandoz signs on to lead launch of Pear's digital therapeutics
A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'
Lessons learned from going live on Facebook with a branded drug
Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.
Can the healthcare industry really expect to drive patient engagement?
Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.
Five things for pharma marketers to know: Tuesday, April 24, 2018
Express Scripts pressures Amgen on migraine medicine list price; Takeda, Shire get closer to deal; Sanofi R&D chief steps down.
Five things for pharma marketers to know: Monday, April 23, 2018
Takeda makes higher offer for Shire; Prothena pulls plug on AL amyloidosis drug; Henry Schein to spin off animal health unit.
Five things for pharma marketers to know: Friday, April 20, 2018
Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.
P&G: healthcare acquisition helps us stay on top of consumer 'megatrends'
Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.
Private-equity funds dominate marcomms M&A
Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.
Five things for pharma marketers to know: Thursday, April 19, 2018
Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
Read and Scott: 'We don't believe break-up of WPP makes sense'
WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.
Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'
Seifert said feedback from clients has been positive.
PBMs, drugmakers face off over copay accumulators
As with most drug pricing battles, patients yet again are caught in the crossfire.
Five things for pharma marketers to know: Wednesday, April 18, 2018
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.
The MM&M buyer's guide to boutique consulting services
You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.
Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'
The healthcare marketing group made another major acquisition in the country last month.
Omnicom beats estimates in Q1, but sees slight dip in North America
Omnicom's healthcare revenue was up 2.7% in Q1
Five things for pharma marketers to know: Tuesday, April 18, 2018
J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.
Sorrell on Sorrell: ex-WPP chief in his own words
Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.
